CEO Brian Moynihan highlights health benefits and cost savings for employees
Category: Business
Bank of America is making headlines with its substantial annual investment of over $250 million in GLP-1 weight loss medications for its employees. This bold move reflects the bank's commitment to enhancing employee health and well-being, as CEO Brian Moynihan emphasized during a recent discussion at the Aspen Economic Strategy Group annual meeting in 2026. Such investments are not just about immediate costs; they represent a strategic approach to long-term health benefits and potential savings on healthcare expenditures.
Bank of America has dramatically increased its spending on GLP-1 drugs, which include popular medications like Novo Nordisk's Ozempic and Wegovy, as well as Eli Lilly's Zepbound. "We spend about $250 million or more on GLPs, and that's up from zero four or five years ago," Moynihan told CNBC's Andrew Ross Sorkin. The bank's annual healthcare budget exceeds $2 billion, with GLP-1 medications now accounting for approximately 13% of total healthcare spending, highlighting the rapid growth in demand for these treatments.
Moynihan argues that the investment is justified due to the health benefits these medications provide, which include a reduced risk of heart disease and other obesity-related complications. He stated, "We see a great impact on the employees," indicating that the bank's approach has already shown measurable results in employee health. By combining access to GLP-1 medications with health coaching programs, Bank of America aims to support its employees in managing weight loss and improving their nutrition, which can lead to long-term lifestyle changes.
Bank of America’s strategy stands in stark relief against that of other employers. According to a 2026 survey by the International Foundation of Employee Benefit Plans, only 36% of companies provide coverage for GLP-1 medications for diabetes and weight loss. Some large employers, such as PwC, have reportedly stopped covering these drugs altogether, citing the high costs associated with obesity treatments. This discrepancy raises questions about how businesses balance employee health needs with financial sustainability.
As demand for GLP-1 medications grows, some employees are facing challenges related to insurance coverage and affordability. Reports indicate that changes in insurance policies have made it difficult for some individuals to afford these necessary medications, creating a precarious situation where financial and physical health are at odds. The trend has led to discussions among HR professionals about how to manage the increasing prevalence of these drugs within the workforce.
The future of GLP-1 medications in corporate America remains uncertain but promising. Drug manufacturers like Eli Lilly and Novo Nordisk are actively working to expand employer coverage, viewing workplace insurance as a key pathway for broader adoption of their treatments. Earlier this year, Lilly introduced a new program allowing companies to purchase a multi-dose version of Zepbound at a net price of $449 per month, which could provide businesses with more flexibility in designing their prescription benefits.
The discussion surrounding GLP-1 medications is indicative of a larger trend in healthcare, where employers are increasingly recognizing the importance of investing in employee health. Moynihan acknowledged that not every employee who benefits from these medications will remain at Bank of America long enough for the company to reap the full rewards of its investment. Nonetheless, he views this initiative as part of a broader strategy to provide meaningful benefits that improve workforce health.
As more companies navigate the complex dynamics of healthcare spending and employee wellness, Bank of America’s approach could serve as a model for others. The bank's willingness to invest heavily in GLP-1 drugs reflects a shift in how businesses view healthcare costs—not merely as an expense but as a key component of employee satisfaction and productivity. With healthcare costs continuing to rise, the implications of such investments may extend far beyond the corporate balance sheet.
In light of these developments, the conversation around GLP-1 medications is likely to evolve as more employers weigh the financial implications against the potential health benefits for their workforce. With the increasing prevalence of obesity and related health issues in the United States, the demand for effective treatments like GLP-1 drugs is expected to grow. As this trend continues, companies will need to carefully assess their healthcare strategies to balance costs with employee health outcomes, ensuring that they are prepared for the future of workplace wellness.
As Bank of America leads the way in this innovative approach to employee health, other companies may soon find themselves reconsidering their own healthcare policies and the role that medications like GLP-1s can play in fostering a healthier workforce.